Bioactive peptides are short chains of amino acids responsible for modulating various physiological functions in the human body. They are considered building blocks of proteins and are released during the digestion of milk, meat, and plant proteins. Bioactive peptides have various health benefits such as antioxidative, antihypertensive, anticariogenic, antidiabetic, and immuno-enhancing properties. They help in preventing various chronic diseases and improving gut health.
The global bioactive peptide market is estimated to be valued at US$ 11.29 Bn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
High prevalence of these diseases has increased demand for functional foods and nutraceuticals containing bioactive peptides. According to WHO, cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. Bioactive peptides modulate blood pressure and help prevent hypertension which is a primary risk factor for heart diseases and stroke. Their ability to reduce blood glucose levels and aid weight management also lowers the risk of diabetes. This major opportunity of disease prevention through bioactive peptides is expected to fuel significant growth of the market over the forecast period.
Porter’s Analysis
Threat of new entrants: Low capital requirements and established intellectual property rights pose low threat of new entrants. However, sustained R&D investment and clinical trials pose high barriers.
Bargaining power of buyers: Large buyers like food and beverage companies have significant bargaining power due to the consolidated nature of the industry.
Bargaining power of suppliers: Suppliers of raw materials like milk proteins have moderate bargaining power due to the specialized technical expertise required.
Threat of new substitutes: Potential threat from new protein sources like plant-based proteins and lab-grown meat substitutes.
Competitive rivalry: High competition with focus on product innovation, quality, and intellectual property. Market leaders focus on strategic collaborations and acquisitions.
SWOT Analysis
Strengths: Growing health and wellness trend drives demand. Extensive R&D expands applications in nutrition, pharmaceutical and personal care markets.
Weaknesses: High dependence on few suppliers increases supply chain risks. Stringent regulatory approvals delay product launches.
Opportunities: Untapped growth potential in emerging Asian and Latin American markets. Innovations to develop disease-specific peptides increase commercialization.
Threats: Rising raw material prices and trade policies affect profit margins. Increased awareness about potential side effects impacts brand image.
Key Takeaways
The Global Bioactive Peptide Market Size is expected to witness high growth over the forecast period of 2024 to 2031.
Regional analysis: Asia Pacific region is expected to grow at the fastest rate during the forecast period. Rising middle-class population, increasing health awareness, and growing spending on healthcare and wellness supplements are driving the market in the region. China, India, and Japan account for the majority share of the Asia Pacific bioactive peptides market.
Key players: Key players operating in the bioactive peptide market are Archer Daniels Midland Company, Kerry Group, Cargill, Incorporated, DSM Nutritional Products, Chr. Hansen Holdings, Nestle SA, Abbott Nutrition, FrieslandCampina. Archer Daniels Midland Company, Kerry Group and Cargill, Incorporated hold the largest market shares.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it